Directors, Supervisors and Senior Management

Directors, Supervisors and Senior Management

Mr. Yu Qingming

. . . .Secretary of Party Committee, chairman, executive director and Authorized Representatives

Mr. Yu Qingming, aged 57, is the secretary of Party Committee, chairman and executive Director of the Company. Mr. Yu has over 34 years of working experience, especially in the management of pharmaceuticals, medical devices and health products, and holds the professional title of senior engineer. Mr. Yu graduated from Shanghai Medical Equipment College (now known as University of Shanghai for Science and Technology) in 1987, and graduated from the Central Party School majoring in economic management in July 2001 with a master degree. From July 1987 to February 1997, Mr. Yu successively worked at Beijing Pharmaceutical Station of CNPGC, China Medical Instrument Corporation and State Pharmaceutical Administration; from February 1997 to August 2010, Mr. Yu successively held senior management positions in Zhuhai United Laboratories Co., Ltd. and China Medical Instrument Corporation. Mr. Yu has taken senior management positions of China National Scientific Instruments and Materials Co., Ltd. and China National Medical Device Co., Ltd. since August 2010. He currently served as the chairman of China National Scientific Instruments and Materials Co., Ltd. and China National Medical Device Co., Ltd.. Mr. Yu joined the Group since November 2018 and currently served as secretary of Party Committee, chairman, executive Director and authorized representative of the Company. Mr. Yu served as director and general manager of Sinopharm Investment since March 2021. Mr. Yu is currently also a representative of the 13th National People’s Congress, a member of the 13th Beijing Chaoyang District of Chinese People’s Political Consultative Conference, vice president of China Association for Medical Devices Industry, vice chairman of China Association of Medical Equipment, and vice president of China Association for Vaccines etc. He is appointed as part-time professor in various universities such as East China University of Science and Technology and Beijing Jiaotong University (formerly known as Northern Jiaotong University).

Mr. Liu Yong

. . . .President, Deputy Secretary of Party Committee and executive Director

Mr. Liu Yong, aged 52, is an executive Director, president and deputy secretary of Party Committee of the Company. Mr. Liu has over 29 years of working experience, over 26 years of which is management experience in the pharmaceutical and healthcare products industry. Mr. Liu obtained a bachelor’s degree in science, majoring in business administration of pharmaceutical enterprises, from China Pharmaceutical University in July 1992, a master’s degree in business administration from Fudan University in January 2000 and a doctoral degree in social and administrative pharmacy from China Pharmaceutical University in June 2016. Mr. Liu is a chief pharmacist and a practicing pharmacist. Mr. Liu joined the Group since July 1992. He worked at Shanghai Pharmaceutical Station, China National Pharmaceutical Group Shanghai Co., Ltd., Shanghai Guoda Drug Chain Store Co., Ltd. and Sinopharm Holding Shenyang Co., Ltd.. Mr. Liu held senior management positions in the Company since January 2009, and is currently also an executive Director, president and deputy secretary of Party Committee of the Company. Mr. Liu currently serves as the director of Sinopharm Investment and Sinopharm (CNCM LTD), the chairman of Sinopharm Accord, and also takes senior management positions in a number of subsidiaries.

Mr. Chen Qiyu

. . . .Non-executive Director & Vice Chairman

Mr. Chen Qiyu, aged 49, is a non-executive Director and vice chairman of the Company. Mr. Chen has over 28 years of working experience. He obtained a bachelor’s degree in genetics from Fudan University in July 1993 and an executive master’s degree in business administration from China Europe International Business School in September 2005. Mr. Chen joined Fosun Pharma since 1994, and is currently the non-executive director of Fosun Pharma and executive director of Fosun International, non-executive director and chairman of the Board of Directors of Henlius, co-chairman of New Frontier Health Corporation (a company listed on the New York Stock Exchange, stock code: NFH) and director of Beijing Sanyuan Food Co., Ltd. (a company listed on the Shanghai Stock Exchange, stock code: 600429) and chairman of Shanghai Fosun High Technology (Group) Co., Ltd.. Mr. Chen has served as the director of Di’an Diagnostics Group Co., Ltd. (迪安診斷技術集團股份有限公司) (a company listed on the growth enterprise board of the Shenzhen Stock Exchange, stock code: 300244) and Maxigen Biotech Inc. (a company listed on the Taiwan Stock Exchange, stock code: 1783), and non-executive director of Babytree (a company listed on the Hong Kong Stock Exchange). Mr. Chen joined the Company in January 2003, and has served as the chief Supervisor and non-executive Director of the Company, and is currently the non-executive Director and vice chairman of the Company. Mr. Chen is also the deputy chairman of Sinopharm Investment. Mr. Chen is currently also the chairman of China Medical Pharmaceutical Material Association, vice chairman of China Association for Pharmaceutical Innovation, honorary chairman and chief supervisor of Shanghai Biopharmaceutics Industry Association, the vice-chief of Shanghai Society of Genetics and the standing member of the 13th Shanghai Committee of the Chinese People’s Political Consultative Conference.

Mr. Ma Ping

. . . .Non-executive Director

Mr. Ma Ping, aged 65, is a non-executive Director of the Company. Mr. Ma has over 38 years of working experience and currently serves as an external director of CNPGC. Mr. Ma received a bachelor degree from chemistry department of Fudan University in 1982. Mr. Ma worked at Ministry of Labor and Personnel, National Pharmaceutical Administration and State Planning Commission from February 1982 to March 1992. He also took senior management positions in London Export Corporation, Hoechst (China), Lotus Healthcare, BMP, Sinogen International Ltd. and United Medical Industrial Group respectively from March 1992 to March 2000. He served as director and vice general manager of Tonghua Golden-horse Group (a company listed on Shenzhen Stock Exchange, stock code: 000766) from March 2000 to September 2001. He served as director and general manager of BMP (a company listed on Nasdaq, stock code: BJGP) from September 2001 to December 2005. He currently serves as director of BioPro Pharmaceutical Inc. and project consultant of Principle Capital. He has been serving as an external director of CNPGC since May 2016. Mr. Ma is also the director of China National Biotec Group Co., Ltd.. Mr. Ma has been serving as non-executive Director of the Company since joining the Company in October 2016.

Mr. Hu Jianwei

. . . .Non-executive Director

Mr. Hu Jianwei, aged 47, is a non-executive Director of the Company. Mr. Hu worked at government agencies for a long time from July 1994 to November 2017. He has in-depth research on macroeconomic operation and management and is familiar with medical and health work. He has served as a member of Party Committee and deputy general manager of CNPGC since December 2017, and general counsel since January 2019, mainly responsible for work such as strategic planning, branding, operation and legal affairs. Mr. Hu has served as nonexecutive Director of the Company since he joined the Company in December 2018.

Mr. Deng Jindong

. . . .Non-executive Director

Mr. Deng Jindong, aged 57, is a non-executive Director of the Company. He has over 33 years of working experience, over 28 years of which is financial management experience. Mr. Deng obtained a bachelor’s degree in economics from Hangzhou Electronics Industry Institution (currently known as Hangzhou Dianzi University) in July 1986 and a master’s degree in economics from Central Institute of Finance and Economics (currently known as Central University of Finance & Economics) in January 1991. He is a non-practicing PRC certified public accountant. Mr. Deng was previously the chief financial officer of Economic Information Network Data Co., Ltd., senior audit manager of Taikang Life Insurance Co., Ltd. and the head of the finance department of CNPGC from April 2000 to October 2004. Mr. Deng has been the chief accountant of CNPGC from October 2004 to May 2017, and has served as its vice general manager since May 2017. Mr. Deng has been a non-executive Director since he joined the Company in August 2007. He is currently also the chairman of Sinopharm Investment.

Mr. Wen Deyong

. . . .Non-executive Director

Mr. Wen Deyong, aged 50, is a non-executive Director of the Company. Mr. Wen graduated from Donghua University and received a master’s degree in business administration in December 2007. Mr. Wen joined Fosun Pharma in May 2002, and is currently the senior vice president of Fosun Pharma and joint president of Shanghai Fosun Pharmaceutical Industry Development Co., Ltd.. Mr. Wen worked at Chongqing Yaoyou Pharmaceutical Co., Ltd. and Chongqing Haisiman Company from September 1995 to May 2016. Mr. Wen has served as the non-executive Director of the Company since September 2017. Mr. Wen is currently also the director of Sinopharm Investment and the director of Sinopharm (CNCM LTD).

Ms. Guan Xiaohui

. . . .Non-executive Director

Ms. Guan Xiaohui, aged 50, has served as a non-executive Director of the Company since March 2019. Ms. Guan tendered her resignation as a non-executive Director of the Company in March 2021, which shall be subject to the approval of her replacement at the general meeting. Ms. Guan obtained a bachelor’s degree in economics from Jiangxi University of Finance and Economics and obtained a master’s degree in accounting for senior accountant from the Chinese University of Hong Kong in December 2007. Ms. Guan is qualified as Chinese Certified Public Account (CPA) and a member of The Association of Chartered Certified Accountants (ACCA). Ms. Guan joined Fosun Pharmaceutical in May 2000 and currently serves as an executive president and chief financial officer of Fosun Pharmaceutical. Ms. Guan worked at Jiangxi Provincial Branch of the Industrial and Commercial Bank of China from July 1992 to May 2000. Ms. Guan once served as a supervisor of Sinopharm Accord. Ms. Guan currently also serves as a non-executive director of Henlius, a director of Gland Pharma Limited (a company listed on Bombay Stock Exchange Limited and National Stock Exchange of India, stock code: GLAND and GLAND) and a supervisor of Sinopharm Investment.

Ms. Feng Rongli

. . . .Non-executive Director

Ms. Feng Rongli, aged 46, is a non-executive Director of the Company. Ms. Feng graduated from Shanghai University with a major in microcomputer application in July 1996 and obtained a master’s degree in business administration from Columbia Southern University in February 2002. Ms. Feng has extensive experience in the field of human resources management. Ms. Feng held human resources management positions in Sealed Air Packaging (Shanghai) Co., Ltd. (希悅爾包裝(上海)有限公司), Grundfos Pumps (Shanghai) Co., Ltd. (格蘭富水泵(上 海)有限公司), Emerson Electric (China) Holdings Co., Ltd. (艾默生電氣(中國)投資有限公司), Dow Chemical (China) Co., Ltd. (陶氏化學(中國)有限公司), Shanghai Roche Pharmaceutical Co., Ltd. (上海羅氏製藥有限公司), and F. Hoffmann-La Roche AG from July 1996 to February 2015. Ms. Feng served as the deputy chief human resources officer of Fosun High Technology and the managing director of the human resources of Shanghai Fosun Venture Capital Investment Management Co., Ltd. (上海複星創業投資管理有限公司) from July 2018 to April 2020. Ms. Feng has served as the vice president of Fosun Pharma since April 2020 and served as the senior vice president of Fosun Pharma since March 2021. Ms. Feng currently serves as the chairman of the supervisory committee of Henlius. Ms. Feng has served as the non-executive Director of the Company since June 2020.

Mr. Zhuo Fumin

. . . .Independent non-executive Director

Mr. Zhuo Fumin, aged 70, is an independent non-executive Director of the Company. Mr. Zhuo has more than 45 years of experience in the field of enterprise management and capital markets. Mr. Zhuo graduated from Shanghai Jiaotong University of Engineering Science in 1983. He subsequently obtained a master’s degree in economics from Fudan University in 1997. Mr. Zhuo currently serves as chairman and managing partner of V Star Capital. Between 1987 and 1995, Mr. Zhuo served senior positions including an office head and an officer assistant of the Shanghai Economic System Reform Committee. Between 1995 and 2002, Mr. Zhuo held in turn various senior management positions at Shanghai Industrial Investment (Holdings) Co., Ltd.. Mr. Zhuo has served as the chairman and the chief executive officer of Vertex China Investment Co., Ltd. (a wholly owned subsidiary of Vertex Management Group, a global venture capital management company), founder and chairman of Shanghai Kexing Investment Co., Ltd. and managing partner of GGV Capital, a venture capital fund since 2002. Mr. Zhuo has served as the independent non-executive Director of the Company since March 2016. Mr. Zhuo is also an independent director of Arcplus Group Plc (a company listed on the Shanghai Stock Exchange, stock code: 600629) and Daqo New Energy Corp. (a company listed on the New York Stock Exchange, stock code: DQ), Focus Media (a company listed on the Shenzhen Stock Exchange, stock code: 002027), Shanghai ShineLink International Logistics Co., Ltd. (a company listed on the Shanghai Stock Exchange, stock code: 603648) and Dazhong Transportation (Group) Co., Ltd. (a company listed on the Shanghai Stock Exchange, stock code: 600611), a non-executive director of Besunyen Holdings Company Limited (a company listed on the Hong Kong Stock Exchange, stock code: 926), and an independent non-executive director of SRE Group Limited (a company listed on the Hong Kong Stock Exchange, stock code: 1207).

Mr. Chen Fangruo

. . . .Independent non-executive Director

Mr. Chen Fangruo, aged 56, graduated from Shanghai Jiao Tong University in 1985 with dual Bachelor’s Degrees in Shipbuilding and Marine Engineering and Computer Science and Technology. In 1987, he obtained a Master’s Degree from the Moore School of Electrical Engineering, University of Pennsylvania. He then received his Ph.D. degree from the Wharton School at the University of Pennsylvania. Mr. Chen worked at Columbia Business School in 1992, successively serving as the Assistant Professor, Associate Professor, Lifetime Associate Professor, and Full Professor. In 2005, he became the Lifetime Chair Professor. During the foregoing period, Mr. Chen acted as a distinguished visiting professor at Stanford School of Business, Cheung Kong Graduate School of Business, Chinese Academy of Sciences, Shanghai Jiao Tong University, Peking University, Tianjin University and other prestigious universities at home and abroad. Mr. Chen has served as the independent non-executive Director of the Company since December 2018. Mr. Chen has served as a visiting chair professor at Shanghai Jiao Tong University since 2017. He is currently a “Guangqi” fund sponsored professor at Shanghai Jiao Tong University, the Dean of Antai College of Economics and Management at Shanghai Jiao Tong University, and concurrently as the Dean of the Industry Research Institute of Shanghai Jiao Tong University. Since 2019, he has served concurrently as the vice chairman of the National MBA Education Instruction Committee and a director of the AMBA & BGA’s International Management Board.

Mr. Li Peiyu

. . . .Independent non-executive Director

Mr. Li Peiyu, aged 58, is an independent non-executive Director of the Company. Mr. Li obtained a bachelor’s degree of engineering in Power System and Automation from Tsinghua University, a master’s degree of engineering in Management Engineering from the Department of Economics, School of Economics and Management, Tsinghua University, and PhD of management in Management Science and Engineering from School of Economics and Management, Tsinghua University in July 1984, July 1987 and January 2004, respectively, and obtained a Master of Public Administration (MPA) from Harvard University in June 1998. Mr. Li has worked in the areas of economics, finance and management for more than 30 years. From July 1987 to September 2000, he held positions in the Development Research Center of the State Council. From September 2000 to December 2007, Mr. Li successively served as the deputy director of Henan Provincial Development Planning Committee and the mayor of Hebi City in Henan Province. From December 2007 to November 2020, Mr. Li successively served as director of alternative investment department of China Investment Corporation, inspector of the research office of the State Council, chairman of China Reinsurance (Group) Corporation, and managing director of Beijing Zhongyu Green Investment Management Co., Ltd. and managing director of CASIC Investment Fund Management (Beijing) Limited Company ( 航太科工投資基金管理(北京)有限公司). Mr. Li has served as the independent non-executive Director of the Company since September 2020. Mr. Li has served as the partner of the Beijing Qiyuanhouji Investment Management Co., Ltd (北京啟源厚積投資管理有限公司) since November 2020.

Mr. Wu Tak Lung

. . . .Independent non-executive Director

Mr. Wu Tak Lung, aged 56, is an independent non-executive Director of the Company. Mr. Wu received a bachelor’s degree in Business Administration from the Hong Kong Baptist University in 1993 and a master’s degree in business administration jointly from the University of Manchester and the University of Wales in 2001. Mr. Wu currently serves as an independent non-executive director of Sinomax Group Limited (a company listed on the Hong Kong Stock Exchange, stock code: 1418), China Machinery Engineering Corporation (a company listed on the Hong Kong Stock Exchange, stock code: 1829), Kam Hing International Holdings Limited (a company listed on the Hong Kong Stock Exchange, stock code: 2307), Henan Jinma Energy Company Limited (a company listed on the Hong Kong Stock Exchange, stock code: 6885), Zhongguancun Science-Tech Leasing Co., Ltd. (a company listed on the Hong Kong Stock Exchange, stock code: 1601) and Minth Group Limited (a company listed on the Hong Kong Stock Exchange, stock code: 425). In the last three years, Mr. Wu was an independent non-executive director of Sinotrans Shipping Limited (a company formerly listed on the Hong Kong Stock Exchange and delisted in January 2019, former stock code: 00368), Huarong Investment Stock Corporation Limited (a company listed on the Hong Kong Stock Exchange, stock code: 02277), First Tractor Company Limited (a company listed on the Hong Kong Stock Exchange and the Shanghai Stock Exchange, stock code: 00038 (H Share)/601038 (A Share)), Olympic Circuit Technology Co., Ltd. (a company listed on the Shanghai Stock Exchange, stock code: 603920) and Beijing Media Corporation Limited (a company listed on the Hong Kong Stock Exchange, stock code: 1000). Mr. Wu had worked in Deloitte Touche Tohmatsu, an international accounting firm, for five years. Mr. Wu has served as the independent non-executive Director of the Company since September 2020. Mr. Wu is currently a member of Hong Kong Institute of Certified Public Accountants, a fellow member of Hong Kong Securities and Investment Institute, the Association of Chartered Certified Accountants, the Taxation Institute of Hong Kong, and the Hong Kong Institute of Chartered Secretaries.

Mr. Yu Weifeng

. . . .Independent non-executive Director

Mr. Yu Weifeng, aged 50, is an independent non-executive Director of the Company. Mr. Yu is a lawyer with more than 25 years of working experience as a practicing lawyer. Mr. Yu obtained a bachelor’s degree in laws from Fudan University in June 1995 and a master’s degree in business administration from China Europe International Business School in July 2015. In July 2019, he completed the Senior Management Leadership Program of Harvard Business School. From July 1995 to December 1998, Mr. Yu served as a paralegal and lawyer in Shanghai Pu Dong International Law Office (now renamed as Shanghai Pu Dong Law Office); Mr. Yu has served as a partner in Links Law Offices since December 1998, and served as a director thereof from January 2014 to June 2020. Mr. Yu currently serves as an independent director of Deppon Logistics Co., Ltd. (a company listed on the Shanghai Stock Exchange, stock code: 603056) and Shenergy Company Limited (a company listed on the Shanghai Stock Exchange, stock code: 600642) and an external director of Jiahua Chemicals Inc.. Mr. Yu has served as the independent non-executive Director of the Company since September 2020. Currently, Mr. Yu is also an executive councillor of the All China Lawyers Association, director of Foreign Affairs Committee of the All China Lawyers Association, president of Shanghai Arbitration Association, a member of the Administrative Review Committee of Shanghai Municipal People’s Government, special consultant of Shanghai Higher People’s Court, an arbitrator of Shanghai International Economic and Trade Arbitration Commission (Shanghai International Arbitration Center), an arbitrator of Shanghai Arbitration Commission, etc.

EN
Top